A Post-market Prospective Clinical Study of Eurosilicone Luna Mammary Implants
A Prospective, Multi-centre, Observational, Non-comparative, Post-marketing Surveillance Study to Obtain Clinical Outcome Data on the Eurosilicone LunaXT Range of Silicone Breast Implants When Used in Breast Implantation.
研究概览
地位
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:GCA Clinical affairs department
- 电话号码:+33 783326098
- 邮箱:luna10PMCF@gcaesthetics.com
学习地点
-
-
-
Villefranche-sur-Saône、法国
- 招聘中
- Dr Guillaume Lasserre
-
接触:
- Dr Guillaume Lasserre
- 邮箱:dr.lasserre.guillaume@orange.fr
-
首席研究员:
- Guillaume Lasserre
-
-
-
-
-
Barcelona、西班牙
- 招聘中
- DScultp Clinic
-
接触:
- Dr David Sanz
- 邮箱:administracion@plasticabarcelona.com
-
首席研究员:
- David Sanz
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- The target population includes subjects undergoing augmentation or reconstructive breast implant surgery in which the Eurosilicone Luna mammary implant is recommended.
Inclusion criteria are:
- Genetic female subjects aged between 18 and 65 years old.
- Subjects who underwent single or bilateral breast implantation with the study device for one of the following reasons:
i. Primary breast reconstruction following mastectomy (both for one-stage or two-stage surgeries, including patients with previous radiotherapy and who have ADMs (synthetic or natural).
ii. Primary breast augmentation (cosmetic surgery) with or without mastopexy iii. Breast revision surgery with or without mastopexy c) Subjects who have received a Eurosilicone Luna implant. d) Subjects who have provided informed consent and can adhere to the requirements of follow-up appointments as per the study protocol.
Exclusion criteria are:
- Subjects with a BMI >35.
- Subjects with autoimmune disease, lung fibrocystic disease, conditions that interfere with wound healing and blood clotting, a weakened immune system, reduced blood supply to the breast tissue or any other condition for which breast implants are contraindicated.
- Subjects who have participated in a clinical study which involve chemical or drug study within 3 months prior to surgery, with the exception of subjects who are participating in breast cancer-related clinical studies.
- Subjects with insufficient tissue covering due to either radiation damage on the chest wall, tight thoracic skin grafts or radical resection of the pectoralis major muscle.
- Subjects who, in the Investigator's clinical opinion, have existing local or metastatic carcinoma of the breast that is unlikely to be fully excised at the time of insertion of the breast implant.
- Subjects with known previous history of a sensitivity to silicone who, in the opinion of the Investigator, are unsuitable for surgery.
- Subjects with an active infection who are unsuitable for surgery unless, in the opinion of the investigator, they are treated and cleared by the investigator.
- Subjects with a history of abscesses anywhere in the body who, in the opinion of the Investigator, are unsuitable for surgery.
- Subjects with a known history of compromised wound healing.
- Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.
- Women who are pregnant and/or current breast feeders who do not stop breast feeding within 3 months of getting breast implants.
- Patients who have local recurrence or metastatic carcinoma at the time of insertion of breast implant.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Aesthetic indications
Primary or revision breast augmentation with or without mastopexy.
|
The procedure is carried out at the surgeon's discretion.
This includes the incision location, the implant placement, the intraoperative applications.
其他名称:
|
|
Medical indications
Primary or revision of breast reconstruction.
Immediate or delayed reconstruction.
With or without associated chemotherapy and/or radiotherapy.
|
The procedure is carried out at the surgeon's discretion.
This includes the incision location, the implant placement, the intraoperative applications.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Frequency and rate of implant rupture
大体时间:10 years
|
10 years
|
|
Frequency and rate of capsular contracture Baker III-IV
大体时间:10 years
|
10 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Rate of the secondary surgical procedures required for correction of complications
大体时间:10 years
|
10 years
|
|
|
Patient satisfaction
大体时间:10 years
|
This will be determined using a questionnaire assessing the qualify of life.
|
10 years
|
|
Rate and frequency of local complications
大体时间:10 years
|
These complications may be related to the device itself or to the surgical procedure:
|
10 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CLA-0007
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.